MORE►
Julie Sloat
Julie Sloat (left) and Louis Pinkham
Dallas-Based Jacobs Names 2 New Members to Its Board of Directors
by Lance Murray | Nov 10, 2023
The professional services giant named Julie Sloat and Louis Pinkham to its board, bringing experience across business, technology, manufacturing, and energy transition.
Related Articles
Rail Town Roots Meet Tomorrow at Sachse’s Heritage Park With $10M Renovation
Dallas’ Forte Biosciences Announces $53M Private Placement From Leading Healthcare Investors
The Last Word: Gov. Greg Abbott on Texas’ Advanced Nuclear Energy Future
12 North Texas Companies Make the 2024 Deloitte Technology Fast 500 List
Calendar: Not-to-Miss Events for Innovators in Dallas-Fort Worth
MORE►
Trending
North Texas is a big place, with plenty to do, see, hear, and watch. We scour the internet every week to find events and activities for you. As always, things may change at any time, so be sure to check the official website or registration page for the latest details....
What do the Dallas Mavericks, Texas Instruments, State Farm, Lennox and over 700 other companies have in common?
They’ve all discovered that their next big idea might come from a college classroom....
Until recently, the majority of Lee Brown’s academic career and research at Texas Woman’s University had centered on corporate political activities and business-government interaction. But just two short years ago, Brown, the business college’s associate dean of research and an associate professor of management, started delving into artificial intelligence technology....
The reopening of Heritage Park in Sachse is another example of what happens when city leaders and developers join forces. After a two-year renovation, a newly reimagined 34-acre “landmark park” in the city pays homage to its past while designing for the future....
Dallas-based Colossal Foundation has given a $1.5 million donation to the University of Melbourne in Australia to support Australian avian conservation genomics, the foundation announced.
The donation will drive the development of an advanced genomics toolkit that will spearhead new approaches to the conservation of bird species in Australia and around the world....
Dallas-based clinical-stage biopharmaceutical company Forte Biosciences Inc. (Nasdaq: FBRX) announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of its FB102, a proprietary molecule with potentially broad autoimmune and autoimmune-related applications....
Trending
North Texas is a big place, with plenty to do, see, hear, and watch. We scour the internet every week to find events and activities for you. As always, things may change at any time, so be sure to check the official website or registration page for the latest details....
What do the Dallas Mavericks, Texas Instruments, State Farm, Lennox and over 700 other companies have in common?
They’ve all discovered that their next big idea might come from a college classroom....
Until recently, the majority of Lee Brown’s academic career and research at Texas Woman’s University had centered on corporate political activities and business-government interaction. But just two short years ago, Brown, the business college’s associate dean of research and an associate professor of management, started delving into artificial intelligence technology....
The reopening of Heritage Park in Sachse is another example of what happens when city leaders and developers join forces. After a two-year renovation, a newly reimagined 34-acre “landmark park” in the city pays homage to its past while designing for the future....
Dallas-based Colossal Foundation has given a $1.5 million donation to the University of Melbourne in Australia to support Australian avian conservation genomics, the foundation announced.
The donation will drive the development of an advanced genomics toolkit that will spearhead new approaches to the conservation of bird species in Australia and around the world....
Dallas-based clinical-stage biopharmaceutical company Forte Biosciences Inc. (Nasdaq: FBRX) announced an oversubscribed $53 million equity financing to support the continuing clinical advancement of its FB102, a proprietary molecule with potentially broad autoimmune and autoimmune-related applications....
